Skip to content

Vor Biopharma VOR Shares (Basic)

Shares (Basic) at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
2.4B+0.1%
Amgen logo
AmgenAMGN
540M+0.4%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
254.1M-1.1%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
48M+34.2%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
61.4M+8.2%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
58.3M+36.5%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,594%
Enterprise value$617.68M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's shares (basic)?
Vor Biopharma (VOR) reported shares (basic) of 43M in Q1 2026.
How has Vor Biopharma's shares (basic) changed year-over-year?
Vor Biopharma's shares (basic) increased by 589.2% year-over-year, from 6.2M to 43M.
What is the long-term trend for Vor Biopharma's shares (basic)?
Over 3 years (2022 to 2025), Vor Biopharma's shares (basic) has grown at a -0.9% compound annual growth rate (CAGR), from 152.3M to 148.1M.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.